

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-170) PACMILIMAB
 PRONUNCIATION pak mil' i mab
 THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G4, anti-(human programmed cell death-ligand 1) (human monoclonal CX-072 γ 4-chain), disulfide with prodomain protein (synthetic masking moiety and cleavable moiety protease substrate-containing) fusion protein with human monoclonal CX-072 κ -chain, dimer (Source: CAS)
2. Immunoglobulin G4-kappa, anti-(*Homo sapiens* Programmed cell death 1 ligand 1 (PDCD1 ligand 1, B7 homolog 1, CD274 antigen)); *Homo sapiens* monoclonal antibody; γ 4 heavy chain (1-442) [VH (*Homo sapiens*IGHV3-23*03 (93%) –(IGHD)-IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens*IGHG4*01 {hinge[S¹⁰>P(224)], CH3[K¹⁰⁷>del(443)]} (117-442)], (130-264')-disulfide with κ light chain (1'-264') [*N*-terminal region "Mask" (1'-21') -triglycyldiseryldiglycylbis(seryldiglycyl) linker (22'-34') –protease cleavable region (35'-47') –diglycylseryl linker (48'-50') V-KAPPA (*Homo sapiens*IGKV1-39*01 (96%) –IGKJ4*01)[6.3.9] (51'-157') -*Homo sapiens*IGKC*01(158'-264')], dimer (222-222':225-225'')-bisdisulfide (Source: USAN Program chemical consultant)

STRUCTURAL FORMULA

Heavy chain X & X''

EVQLLESGGG	LVQPGGSLRL	SCAASGFTFS	SYAMSWVRQA	PGKLEWVSS	50
IWRNGIVTVY	ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCAKWS	100
AAFQYWGQGT	LVTVSSASTK	GPSVFPPLAPC	SRSTSESTAA	LGCLVKDYFP	150
EPVTVSWNSG	ALTSGVHTFP	AVLQSSGLYS	LSSVVTVPSS	SLGKTTYTCN	200
VDHKPSNTKV	DKRVESEKYP	PCPPCPAPEF	LGGPSVFLFP	PKPKDTLMIS	250
RTPEVTCVVV	DVSQEDPEVQ	FNWYVDGVEV	HNAKTKPREE	QFNSTYRVVS	300
VLTVLHQDWL	NGKEYKCKVS	NKGLPSSIEK	TISKAKGQPR	EPQVYTLPPS	350
QEEMTKNQVS	LTCLVKGFYP	SDIAVEWESN	GQPENNYKTT	PPVLDSDGSF	400
FLYSRLTVDK	SRWQEGNVFS	CSVMHEALHN	HYTQKLSLSL	LG	442

Light chain X' & X'''

QQQSGSGIAL	CPSHFCQLPQ	TGGGSSGGSG	GSGGISSGLL	SGRSDNHGGS	50'
DIQMTQSPSS	LSASVGDRTV	ITCRASQGIS	SYLNWYQQKP	GKAPKLLIYA	100'
ASSLQSGVPS	RFSGSGSGTD	FTLTISLQIP	EDFATYYCQQ	DNGYPTSTFGG	150'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	200'
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	250'
LSSPVTKSFN	RGEC				264'

Disulfide bridges location

11'-16'	11'''-16'''	22-96	22''-96''	73'-138'	73'''-138'''
130-264'	130'''-264'''	143-199	143''-199''	184'-244'	184'''-244'''
222-222''	225-225'''	257-317	257''-317''	363-421	363'''-421'''

Glycosylation sites (N)
 Asn-293 Asn-293''

MOLECULAR FORMULA C₆₇₁₈H₁₀₃₇₄N₁₈₁₀O₂₁₄₄S₄₈ . (non glycosylated)

MOLECULAR WEIGHT	152.34 (non glycosylated)
TRADEMARK	None as yet
SPONSOR	CytomX Therapeutics, Inc.
CODE DESIGNATIONS	CX-072
<u>CAS</u> REGISTRY NUMBER	2145091-51-4
UNII	ZXP96ZI2RA
WHO NUMBER	10938

gbk